StreetInsider.com News Articles

HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology

Wed, 21 Oct 2026 08:31:00 -0400

HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million people
Data analysis is underway, with results anticipated for presentation at a cardiology conference in 2027
With the HEADSTART-ACS and ALIGN-ACS studies, HeartBeam has clinical experience with more than 600 patients in heart attack detection, ahead of its U.S. pivotal study planned for Q1 2027

SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the HEADSTART-ACS

HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology

Wed, 21 Oct 2026 08:31:00 -0400

HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million people
Data analysis is underway, with results anticipated for presentation at a cardiology conference in 2027
With the HEADSTART-ACS and ALIGN-ACS studies, HeartBeam has clinical experience with more than 600 patients in heart attack detection, ahead of its U.S. pivotal study planned for Q1 2027

HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients

Thu, 15 Oct 2026 08:31:00 -0400

HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortium
HeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studies
HEART-CHECK will evaluate whether HeartBeam’s at-home 3D ECG can help clinicians recognize recurrent events earlier in patients recently discharged after ACS

HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients

Thu, 15 Oct 2026 08:31:00 -0400

HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortium
HeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studies
HEART-CHECK will evaluate whether HeartBeam’s at-home 3D ECG can help clinicians recognize recurrent events earlier in patients recently discharged after ACS

Form 4 HeartBeam, Inc. For: Oct 02 Filed by: Elfrink Willem

Fri, 09 Oct 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20261009/27171790.html

Form 4 HeartBeam, Inc. For: Oct 02 Filed by: Ferrari Richard

Fri, 09 Oct 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20261009/27171787.html

Form 4 HeartBeam, Inc. For: Oct 02 Filed by: JAFF MICHAEL R

Fri, 09 Oct 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20261009/27171785.html

Form 4 HeartBeam, Inc. For: Oct 02 Filed by: Ortigas-Wedekind Marga

Fri, 09 Oct 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20261009/27171782.html

Form 4 HeartBeam, Inc. For: Oct 02 Filed by: de Urioste George

Fri, 09 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261009/27171776.html

Form 4 HeartBeam, Inc. For: Oct 02 Filed by: Nelson Kenneth Warwick III

Fri, 09 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261009/27171779.html

H.C. Wainwright Reiterates Neutral Rating on Heartbeam Inc. (BEAT)

Tue, 06 Oct 2026 07:08:01 -0400

H.C. Wainwright analyst Yi Chen reiterated a Neutral rating on Heartbeam Inc. (NASDAQ: BEAT).

The analyst commented: "Yesterday, HeartBeam announced that the FDA has granted Breakthrough Device designation for the HeartBeam System as a tool for assessing potential heart attacks at home. The designation is supported by proof-of-concept data from the 134-patient ALIGN-ACS pilot study. As a reminder, HeartBeam’s 3D ECG technology captures the heart’s electrical signals from three non-coplanar dimensions and enables physicians to evaluate signs of a possible heart attack (or myocardial infarction, MI) when symptoms start. The system provides timely access to clinical-grade ECG data outside the hospital,

HeartBeam stock soars on FDA breakthrough designation

Mon, 05 Oct 2026 11:05:57 -0400

Investing.com -- Heartbeam Inc (NASDAQ:BEAT) shares surged as much as 90% Monday after the company announced the U.S. Food and Drug Administration granted Breakthrough Device Designation for its at-home heart attack assessment tool.

The designation recognizes the potential of HeartBeam's 3D ECG technology to help physicians evaluate signs of a possible heart attack when symptoms start, wherever the patient may be. The FDA granted the designation within 30 days of HeartBeam's request, ahead of the agency's 60-day statutory review period.

The Breakthrough Devices Program provides HeartBeam with prioritized FDA review and interaction throughout development, including collaboration on the clinical

HeartBeam stock soars on FDA breakthrough designation

Mon, 05 Oct 2026 11:05:57 -0400

The Breakthrough Devices Program provides HeartBeam with prioritized FDA review and interaction throughout development, including collaboration on the clinical

Commercial Orders, FDA Firepower and Crypto Momentum

Mon, 05 Oct 2026 10:39:10 -0400

DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s headlines include Kraig Biocraft Laboratories (OTCQB: KBLB), HeartBeam (NASDAQ: BEAT), QTREX Quantum (NASDAQ: QTEX), and Veea Inc. (NASDAQ: VEEA).